Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids.

Summerfield, G P; Taylor, W. Rowland; Bellingham, A. J.; Goldsmith, H J

doi:10.1136/jcp.36.9.1005

Cited by 50 publications

(30 citation statements)

References 6 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various therapies, including steroids, chemotherapy, anti-CD20 monoclonal antibody and anti-IL-6 treatment, have been attempted in MCD [4]. Although steroids are often used to manage the symptoms of MCD, disease recurrence is common during steroid tapering [17]. Combination chemotherapies, including cyclophosphamide, vincristine and prednisolone, and cyclophosphamide, adriamycin, vincristine and prednisolone, induced a complete response in approximately 50% of patients; however, relapses are common [3,4].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Yuzuriha¹,

Saitoh²,

Koiso³

et al. 2011

Acta Haematol

View full text Add to dashboard Cite

We describe herein the successful treatment of severe autoimmune hemolytic anemia (AIHA) in a patient with multicentric Castleman disease (MCD) by humanized anti-interleukin-6 (IL-6) receptor antibody (tocilizumab) therapy. Inflammatory anemia is commonly reported; however, AIHA is a very rare complication of MCD. In 1996, a 45-year-old Japanese woman was referred to our hospital because of generalized lymphadenopathy, anemia and skin eruptions. Lymph node biopsy demonstrated MCD. She was treated with prednisolone (1 mg/kg/day), which improved the anemia and skin eruptions. In 2009, she suddenly developed Coombs-positive hemolytic anemia. The blood count was as follows: hemoglobin 4.7 g/dl, platelets 490 × 10⁹/l and white blood cell count 9.8 × 10⁹/l. Both direct and indirect Coombs’ tests were strongly positive. She was treated with 8 mg/kg tocilizumab every 2 weeks. One month later, her hemoglobin levels rose dramatically to 10.9 g/dl and her haptoglobin level, hypergammaglobulinemia and clinical symptoms had also markedly improved. To the best of our knowledge, this is the first report of the efficacy of tocilizumab in AIHA associated with MCD. The well-established role of IL-6 in the pathogenesis of MCD may have been responsible for the improvement in the AIHA associated with MCD. Anti-IL-6 receptor antibody treatment could be an attractive therapeutic approach for AIHA associated with MCD.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Yuzuriha¹,

Saitoh²,

Koiso³

et al. 2011

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…1 The disease is characterized by recurrent lymphadenopathy, fevers, and hepatosplenomegaly, 2 and frequent progression to non-Hodgkin lymphoma. 3 Although no standard of care for the treatment of MCD has been established, symptomatic recurrences are often treated with chemotherapy or radiotherapy, 4 corticosteroids, 5 interferon, 6 or anti-CD20 monoclonal antibodies. 7 No therapy has been shown to significantly reduce exacerbations or to prevent long-term sequelae.…”

Section: Introductionmentioning

confidence: 99%

Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment

Casper

Nichols

Huang

et al. 2004

Blood

181

127

View full text Add to dashboard Cite

“…Only few of the nephrotic patients have been biopsied, and various histological lesions have been described (table l). They ranged from minimal change [15,16] to membranous nephropathy [17,18], interstitial nephritis [19] and amyloidosis [20], The finding of membranoproliferative glomerulonephri tis (MPGN) in our nephrotic patient with ALNH (plasma cell type) is a new one, and to our knowledge, such an association has not been reported previously.…”

Section: Introductionmentioning

confidence: 75%

Membranoproliferative Glomerulonephritis Associated with Multicentric Angiofollicular Lymph Node Hyperplasia

Said

Tarawneh²

1992

Am J Nephrol

View full text Add to dashboard Cite

A 14-year-old boy presented with fever, anemia, hepatosplenomegaly, generalized lymphadenopathy and nephrotic syndrome. Lymph node biopsy showed angiofollicular lymph node hyperplasia (generalized Castleman’s disease) of the plasma cell type. Kidney biopsy showed membranoproliferative glomerulonephritis type 1. Complete remission was achieved with corticosteroid treatment and repeat kidney biopsy 22 months later showed complete resolution of the renal pathology. The association between membranoproliferative glomerulonephritis and multicentric angiofollicular lymph node hyperplasia, plasma cell type, has not previously been reported.

show abstract

Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids.

Cited by 50 publications

References 6 publications

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment

Membranoproliferative Glomerulonephritis Associated with Multicentric Angiofollicular Lymph Node Hyperplasia

Contact Info

Product

Resources

About